Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Ozempic Lawsuits Claim Drug Is Linked to Vision Loss - Featured image
Health

Ozempic Lawsuits Claim Drug Is Linked to Vision Loss

Dr. Adrian Vale, MD
Reviewed by Dr. Adrian Vale, MDInternal Medicine · Board-Certified Obesity Medicine
·December 19, 2025·2 min read

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

Ozempic, along with other weight loss medications, has demonstrated potential in mitigating health risks. However, lawsuits are emerging, alleging a connection between these drugs and vision loss. Patients are filing claims against the manufacturers.

Share

Ozempic Lawsuits Claim Drug Is Linked to Vision Loss

Weight loss drugs like Ozempic have been shown to decrease risks for various health problems, including heart and kidney disease, potentially generating billions in revenue for pharmaceutical companies over the coming decade.

However, in rare instances, GLP-1 agonists, the class of drugs to which Ozempic belongs, can lead to severe side effects. Most notably, blindness has been reported, prompting over 70 lawsuits against Novo Nordisk and Eli Lilly, the makers of Ozempic and Mounjaro, respectively, according to Reuters.

These lawsuits, filed in both state and federal courts, claim that the medications caused patients to develop non-arteritic anterior ischemic optic neuropathy. This condition involves a disruption of blood flow to the optic nerve, resulting in vision loss. Health tracking apps like Shotlee can help monitor for any sudden changes in vision, facilitating early detection and intervention.

A federal judicial panel recently approved the consolidation of these cases, assigning a Pennsylvania federal judge to oversee them. This decision paves the way for a significant legal battle with potentially far-reaching consequences for the future of these increasingly popular drugs.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

Furthermore, the manufacturers of GLP-1 drugs face additional challenges beyond the blindness lawsuits. A separate series of legal actions alleges that these drugs can induce gastroparesis, a condition where the gastrointestinal tract's ability to move food for digestion is impaired.

The first GLP-1 agonist drug received approval from the US Food and Drug Administration (FDA) in 2005 as a treatment for diabetes. Subsequently, in 2021, the FDA authorized Novo Nordisk, the manufacturer of Ozempic, to produce and market Wegovy. Wegovy functions similarly to Ozempic but is specifically targeted towards individuals seeking weight loss.

That important decision, coupled with widespread positive media coverage, sparked the current enthusiasm for these weight loss medications. Celebrities such as Oprah and Rebel Wilson have reportedly experienced significant weight loss in a relatively short period using these drugs.

However, in recent years, an increasing number of individuals have reported experiencing serious side effects from using these medications. This has tempered some of the excitement surrounding drugs that were once promoted as a miracle cure for a wide array of ailments, including aging.

Source Information

Originally published by Futurism.Read the original article →

Read next

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Semaglutide and Tirzepatide: The Reality of Stopping and Restarting
Endocrinology

Semaglutide and Tirzepatide: The Reality of Stopping and Restarting

A groundbreaking analysis of diabetes medication patterns reveals that stopping isn't always permanent. Discover which drugs have the best retention rates and how insurance impacts access.

7 min read
Ozempic and Testosterone: Does Weight Loss Drive Sperm Quality Gains?
Men's Health

Ozempic and Testosterone: Does Weight Loss Drive Sperm Quality Gains?

A comprehensive review of clinical trials suggests that GLP-1 medications may offer reproductive benefits for men with obesity-related low testosterone, potentially surpassing traditional hormone replacement therapies.

7 min read
Beyond Weight Loss: GLP-1 Drugs Show Potential to Reduce Crime-Linked Behavior
Health & Wellness

Beyond Weight Loss: GLP-1 Drugs Show Potential to Reduce Crime-Linked Behavior

Groundbreaking research indicates that GLP-1 receptor agonists, widely recognized for their impact on diabetes and weight management, may also play a crucial role in modulating impulsive behaviors that can lead to criminal acts and violence.

6 min read

Same topic: Pharmaceuticals

All Pharmaceuticals articles →
Wegovy Pill Arrives in the UK: A New Era for Weight Management?
Health & Wellness

Wegovy Pill Arrives in the UK: A New Era for Weight Management?

The UK has officially approved a pill version of the popular Wegovy weight-loss drug, marking a significant advancement in accessible obesity treatment. This development offers a convenient alternative to weekly injections for many.

6 min read
Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation
Health & Wellness

Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation

The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.

7 min read
Beyond Weight Loss: The Next Wave of GLP-1 Drugs
Health & Wellness

Beyond Weight Loss: The Next Wave of GLP-1 Drugs

The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.

7 min read

More in Health

Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise
Medical News

Retatrutide Phase 3 Results: 28% Weight Loss and the Triple Agonist Promise

Eli Lilly has released pivotal Phase 3 trial data for retatrutide, a triple agonist showing up to 28% body weight reduction and significant improvements in diabetes and sleep apnea.

7 min read
Share this article
  1. Home
  2. Blog
  3. Ozempic Lawsuits Claim Drug Is Linked to Vision Loss
Dr. Adrian Vale, MD — Internal Medicine · Board-Certified Obesity Medicine
Medically reviewed

Dr. Adrian Vale, MD

Internal Medicine · Board-Certified Obesity Medicine

Dr. Adrian Vale is a board-certified internal medicine physician with a clinical focus on obesity medicine and metabolic health. He reviews Shotlee guides and articles on GLP-1 medications, peptide therapy, and weight-management protocols for clinical accuracy.

View all articles reviewed by Dr. Adrian Vale, MD
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community